What move does the options market price into C4 Therapeutics's report?

Implied ±15.2%, either direction.

CCCCNasdaqBiological Products, (No Diagnostic Substances)

C4 Therapeutics, Inc. (CCCC) earnings date, market-implied expected move, and options open interest by expiry

3.11

−0.10 · −3.24%

post 3.11 0.00%

After hours16:00 ETdelayed

Open3.24Volume1.6MMkt cap$394.9MEPS-0.91

Day3.05 – 3.3123%52-wk1.69 – 5.1741%

CCCC

C4 Therapeutics, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

Inputs

±15.2%implied · straddle

2.723.70

spot 3.21exp Nov 20ATM strike 3ATM straddle 0.58IV 103%

Nov 3 close

Expected move

Inputs

Next report

Nov 5

before open · in 1 day

est.Q3 FY26

Calendar

Next report

Last report

+6.91%

vs ±20.6% implied · ×0.33

shaded = implied · ▲▼ = realized

Aug 11 '26 · confirmed

Implied vs realized

Linked news

News

Largest filed tie

13F top-10 QoQ

+34.12%

shares held · 10 largest managers

13F · Jun 30 '26127d lag

146 managers

Top fund weight

0.01%

CCCC weight · IWM

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

C4 Therapeutics (CCCC) is expected to report on Nov 5 before open (estimated date).

Implied vs realized

1 report

—≥ implied

Q2 FY26Aug 11 '26confirmed±20.6%▲+6.91%×0.33

quarterimplied−25%0+25%realized×

Q2 FY26±20.6%▲+6.91%×0.33

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 4 expiries · Nov 3 close

1.27OI · 4 expiries · Nov 3 closeP/C open interest · Nov 20 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

6410%Nov 2016d506−7%

2660%Dec 1844d0.221,1880%0.22

2770%Jan 1572d0.0213,7900%0.02

3160%Apr 16163d0.056,1300%0.05

ExpiryPutsCallsP/C

Nov 2016d6410%506−7%1.27

Dec 1844d2660%1,1880%0.22

Jan 1572d2770%13,7900%0.02

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

scenario · straddle±15.2%

Funds 3

IWM±0.0%

UWM±0.0%

VTI±0.0%

Dashed = straddleMethod Source: SEC filings · N-PORT · market data

Linked exposure

Revenue flow

as filedQ2 FY26

−355.90%as filednet margin · revenue +7.95% QoQ · +2.75% YoY

Revenue$7M+7.95%

Gross profit$7M100.00%+7.95%

Operating income−$26M−397.88%+4.90%

Pre-tax income−$24M+5.95%

Net income−$24M−355.90%+5.95%

Cost of revenue$0—

Operating expenses$33M−2.57%

Other income$3M+4.97%

Source: SEC filings · standardized · QE Jun 30 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Long dash = implied range · Nov 3 close · Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:00 ET

Intraday

Event sensitivity

FOMC ×1.96· ±9.0% vs ±4.6% · 24 releases

eventrelease day|move|up · n×base

FOMCrate decision±9.0%11 of 24×1.96

CPIconsumer prices±4.3%5 of 10×0.94

PCEpersonal income & outlays±4.1%12 of 19×0.88

GDPgross domestic product±3.5%10 of 19×0.76

CPROFcorporate profits±3.2%5 of 12×0.71

PPIproducer prices±3.1%3 of 10×0.69

NFPjobs report±2.9%3 of 10×0.63

Bar = avg |move| to ±9% · tick = ±4.6% avg day · ×base = |move| ÷ ±4.6% · min 6 releases

Earnings history

EPS -0.18 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	Aug 11 '26 · confirmed	-0.18	—
Q1 FY26	—	-0.20	—
Q3 FY25	—	-0.44	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod